Press release - 07/10/2020 Joining forces against SARS-CoV-2 Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
Life Science job fair - 28/04/2021 CONTACT2021 Heidelberghttps:////www.gesundheitsindustrie-bw.de/en/event/contact2021
Press release - 05/10/2020 Solar-battery effect enables a new light-driven organic microswimmer to operate in the dark An interdisciplinary team of scientists at the Max Planck Institutes for Intelligent Systems and Solid State Research has developed a biocompatible microswimmer made of carbon nitride, which they can propel forward through light. The particle can also store solar energy similar to miniature solar cells equipped with batteries, and can thus also swim in the dark using the stored energy. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/solar-battery-effect-enables-new-light-driven-organic-microswimmer-operate-dark
Freudenberg Filtration Technologies - 01/10/2020 Coronavirus thwarted: with filters against aerosol spread Filter technology can effectively remove microorganisms such as the new coronavirus from aerosols. A team of experts at Freudenberg Filtration Technologies develops and produces filtration solutions that effectively reduce the spread of viruses in cars, industrial plants and public buildings. The company’s filter technology for reducing the viral load is a reliable method for enabling people to stay in closed rooms with a high density of people.https:////www.gesundheitsindustrie-bw.de/en/article/news/coronavirus-thwarted-filters-against-aerosol-spread
Press release - 25/09/2020 Bosch’s new rapid coronavirus test delivers reliable results in 39 minutes Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/boschs-new-rapid-coronavirus-test-delivers-reliable-results-39-minutes
Organ failure due to fatty liver - 24/09/2020 HepaRegeniX develops an active substance for liver regeneration When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure. https:////www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
Mosses for pharmaceutical production - 16/09/2020 Factor H as a therapeutic option for viral diseases - including COVID-19 The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.https:////www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
Press release - 15/09/2020 ELLIS inaugurates 30 research units at leading institutions across Europe At a virtual event on Tuesday, the European Laboratory for Learning and Intelligent Systems presented the broad scope of research its units will cover in the field of modern AI.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-offizieller-start-der-30-forschungseinheiten-fuehrenden-institutionen-ganz-europa
Phytopharmaceuticals - 14/09/2020 Medicinal cannabis to be grown in Germany Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.https:////www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
Press release - 07/09/2020 Cyber Valley launches Investor Network Europe’s largest AI research consortium attracts interest from some of the world’s most successful venture capital firms.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cyber-valley-gruendet-investor-network
Biochip systems - 02/09/2020 Miniature organs with great potential Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…https:////www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
Press release - 01/09/2020 Strengthening the immune system with small molecules Infections pose an increasing risk to hospitalized patients. In collaboration with a number of partners, the Fraunhofer IGB has developed a new therapeutic approach as part of the InnateFun project. Their strategy is to improve cells’ ability to defend themselves against harmful microorganisms by acting on their immune receptors. The researchers’ work on this therapeutic approach has reached the animal model stage. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/strengthening-immune-system-small-molecules
Press release - 31/08/2020 Radiology researcher receives Humboldt Foundation Sofja Kovalevskaja Award Dr. André Martins from the Department of Radiology at the Tübingen University Hospitals is one of this year's recipients of the Alexander von Humboldt Foundation's Sofja Kovalevskaja Award.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/radiology-researcher-receives-humboldt-foundation-sofja-kovalevskaja-award
Hybrid event - 25/10/2020 - 27/10/2020 World Health Summit 2020 Hybrid event, Online- and on-site conference https:////www.gesundheitsindustrie-bw.de/en/event/world-health-summit-2020
Innovative Therapies - 20/08/2020 Labor Dr. Merk is fully committed to viral therapies Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…https:////www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
Event - 05/10/2020 - 13/11/2020 STARTUP SCHOOL by heiINNOVATION Online, Registration deadline: 31/08/2020, Webinar https:////www.gesundheitsindustrie-bw.de/en/event/startup-school-heiinnovation
Press release - 12/08/2020 New technology provides insight into the development of immune cells The entire range of our blood and immune cells are derived from hematopoietic stem cells. Yet which genes influence how they develop into the different cell types? Scientists from the German Cancer Research Center (DKFZ) have now developed a new technology to answer this question.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-technology-provides-insight-development-immune-cells
Press release - 11/08/2020 Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
Event - 17/09/2020 - 18/09/2020 2nd International Conference on Cancer Prevention online, Registration deadline: 24/08/2020https:////www.gesundheitsindustrie-bw.de/en/event/2nd-international-conference-cancer-prevention
Press release - 06/08/2020 A bridge between artificial intelligence and the life sciences The great potential of artificial intelligence (AI) and machine learning for the life sciences – from basic research in biology to medical applications – has largely been neglected to date. A new research unit aims to support AI research in the life sciences and to forge international links with the activities in Heidelberg.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-life-heidelberg-bridge-between-artificial-intelligence-and-life-sciences
CeGat GmbH - 06/08/2020 Specific coronavirus antibody test for all Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…https:////www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
Event - 05/10/2020 - 16/10/2020 CPhI: Festival of Pharma 2020 Online, Webinar https:////www.gesundheitsindustrie-bw.de/en/event/cphi-festival-pharma-2020
Press release - 28/07/2020 Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it has received regulatory approval to start a clinical phase II trial with asunercept in COVID-19 patients in Russia. The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-start-european-clinical-phase-ii-trial-asunercept-covid-19-patients
TGU Varimol - 24/07/2020 Click chemistry for new medical procedures Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.https:////www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
Press release - 23/07/2020 Images from the inside of blood vessels Smallest 3D printed miniature endoscope in the world detects cholesterol plaques and thrombs inside human and mouse arteries.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/3d-bilder-aus-dem-inneren-von-adern